Thomas B. Campbell MD

Professor of Medicine

Interim Head, Division of Infectious Diseases

Phone:               303-315-8311
E-mail:                Thomas.Campbell@UCHSC.edu
Address:           B168

Medical School

Southwestern Medical school, Dallas TX

Residency

Parkland Memorial Hospital, Dallas TX

Fellowship

University of Colorado Denver

Postdoctoral Fellowship

Dept of Chemistry and Biochemistry at University of Colorado, Boulder, CO

Research Interests

I conduct research to improve the treatment of HIV infection and AIDS-related complications. As Principal Investigator of the Colorado AIDS Clinical Trials Unit I conduct research to optimize the clinical management of HIV-1 infection including the development of improved strategies for administration of antiretroviral therapy, improved management of treatment-related toxicities, and better treatment of multi-drug resistant HIV-1 infection. I am the lead investigator of the first comparative study of antiretroviral efficacy and safety in resource-limited settings around the world. I am Director of the Colorado HIV Research Training Program, which provides support for postdoctoral training in AIDS research at UCD and affiliated institutions. I am Director of the Colorado Center for AIDS Research Virology Core Laboratory, which makes virology tools and services available to University of Colorado investigators for research in AIDS pathogenesis and treatment. I am Associate Program Director of the Colorado Adult General Clinical Research Center, a state-of-the-art facility available to Colorado medical investigators to conduct safe, controlled, inpatient and outpatient studies of humans.

Recent Publications

  1. Campbell TB, Staskus KA, Folkvord J, White IE, Neid J, Zhang X-Q, Connick E. Persistence of Kaposi's sarcoma-associated herpesvirus (KSHV) infected cells in HIV-1 co-infected persons without KSHV-associated diseases. J Infect Dis 2005; 191:367-371.

  2. Flanigan TP, Campbell T, Harwell J, and Kumarasamy N. The extraordinary hope of antiretroviral therapy in South Africa (Even for patients with tuberculosis or Kaposi sarcoma!). J Infect Dis 2005;191:321-323.

  3. Campbell TB, Katzenstein D. Antiretroviral Rounds. Resistance: How do you know if you don't know?. Antiretroviral Rounds. AIDS Clin Care 2005;17.

  4. Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of HIV-1 seroconverters. Clin Infect Dis 2005;40:1355-1357.

  5. Campbell TB, Shulman N, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan T, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy of multidrug-resistant human immunodeficiency virus type 1 infection. Clin Infect Dis 2005;41:236-242.

  6. Campbell TB. Are all HIV-1 created equal? Clin Infect Dis 2006;42:853-854.

  7. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC. HIV-1 specific CD4+ T cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr. 2006;41:140-148.

  8. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kellecher AD, Kaldor J, Routh JP, Campbell TB, Rosenberg E, Schafer K, Wood K, Weidler J, Bates M, Grant RM. Greater CD4+ T cell responses during antiretroviral therapy associates with lower viral pol replication capacity. AIDS 2006;20:2123-2125.

  9. Gripshover B, Santana J, Ribaudo H, Gerber J, Campbell TB, Hogg E, Jarocki B, Hammer S, and Kuritzkes D. A randomized, placebo-controlled trial of amdoxovir vs placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy (AACTG 5118). Antiviral Therapy (in press)

  10. Meditz AL, Borok M, Gudza I, Ndemera B, Gwanzura L, Campbell TB. Sex Differences in AIDS-associated Kaposi's Sarcoma in Zimbabwe. J Acquir Immune Def Syndr (in press).

  11. Boritz E, Rapaport E, Campbell TB, Koeppe JR, Wilson CC. CD4+ T Cell Targeting of HIV-1 peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology (in press)

Grants

  1. NIH P30 AI054907 University of Colorado Center for AIDS Research (CFAR) Virology Core

  2. IH PO1 AI055356 "Immunopathogenesis of Acute HIV-1 Infection", Project 5, "Role of Fitness of Transmitted Virus"

  3. TIBOTEC Pharmaceuticals TMC114-C214, "A Randomized, Controlled, Open-Label, Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment Experienced HIV-1 Infected Subjects."

  4. NIH R21 DE016713 "Significance of Oral KS in an African Setting"

  5. NIH T32 AI007447 "University of Colorado HIV Research Training Program"

  6. Pfizer Pharmaceuticals, Inc. A4001026, "A Multicenter, Randomized, Double-Blind, Comparative Trial of a Novel CCR5 Antagonist, UK-427,857 in Combination with Zidovudine/Lamivudine for the Treatment of Antiretroviral Naïve HIV-1 Infected Subjects."

  7. Pfizer Pharmaceuticals, Inc. A4001027, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857 in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects."

  8. NIH R01 NS036524 "In Vivo Proton MRS Studies; Cerebral Injury in HIV Infection"

  9. Pfizer Pharmaceuticals, Inc. A0081066, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregablin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy."

  10. TIBOTEC Pharmaceuticals TMC125-C229 "An Open-Label Trial with TMC125 in HIV-1 Infected Subjects Who Were Randomized to a TMC125 Treatment Arm in a Sponsor Selected TMC125 Trial and Were Treated for at Least 48 Weeks."

  11. TIBOTEC Pharmaceuticals TMC125-C216 "A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR Regimen in HIV-1 Infected Patients with Limited Treatment Options."

  12. TIBOTEC Pharmaceuticals TMC125-C217 "An Open-Label Trial with TMC125 as Part of an ART Including TMC114/RTV and an Investigator-selected OBR in HIV-1 Infected Subjects Who Participated in a DUET Trial (TMC125-C206 or TMC125-C216)"